Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTRNASDAQ:FGMNASDAQ:FPANASDAQ:FTXH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsFGMFirst Trust Germany AlphaDEX Fund$53.61-0.5%$48.86$35.02▼$55.72$16.08M1.117,656 shs9,062 shsFPAFirst Trust Asia Pacific ex-Japan AlphaDEX Fund$32.17+2.6%$29.45$24.19▼$32.79$16.09M0.952,270 shs644 shsFTXHFirst Trust Nasdaq Pharmaceuticals ETF$25.15+0.2%$25.47$23.29▼$29.72$13.83M0.75,801 shs511 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTRLadRx0.00%0.00%0.00%0.00%0.00%FGMFirst Trust Germany AlphaDEX Fund-0.44%+2.34%+10.46%+24.15%+34.30%FPAFirst Trust Asia Pacific ex-Japan AlphaDEX Fund-1.85%-0.79%+6.09%+4.74%+13.34%FTXHFirst Trust Nasdaq Pharmaceuticals ETF-0.33%+1.05%+2.87%-10.31%-7.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/AFGMFirst Trust Germany AlphaDEX FundN/AN/AN/AN/AN/AN/AN/AN/AFPAFirst Trust Asia Pacific ex-Japan AlphaDEX FundN/AN/AN/AN/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTRLadRx 0.00N/AN/AN/AFGMFirst Trust Germany AlphaDEX Fund 0.00N/AN/AN/AFPAFirst Trust Asia Pacific ex-Japan AlphaDEX Fund 0.00N/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETF 2.59Moderate Buy$25.15N/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTRLadRxN/AN/AN/AN/AN/AN/AFGMFirst Trust Germany AlphaDEX FundN/AN/AN/AN/AN/AN/AFPAFirst Trust Asia Pacific ex-Japan AlphaDEX FundN/AN/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/AFGMFirst Trust Germany AlphaDEX FundN/AN/A13.17∞N/AN/AN/AN/AN/AFPAFirst Trust Asia Pacific ex-Japan AlphaDEX FundN/AN/A11.22∞N/AN/AN/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AN/A16.72∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTRLadRxN/AN/AN/AN/AN/AFGMFirst Trust Germany AlphaDEX Fund$0.831.55%N/AN/AN/AFPAFirst Trust Asia Pacific ex-Japan AlphaDEX Fund$1.023.17%N/AN/AN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETF$0.481.91%N/AN/AN/ALatest CYTR, FGM, FPA, and FTXH DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/26/2025FPAFirst Trust Asia Pacific ex-Japan AlphaDEX FundQuarterly$0.20162.78%3/27/20253/27/20253/31/20253/26/2025FTXHFirst Trust Nasdaq Pharmaceuticals ETFQuarterly$0.09921.45%3/27/20253/27/20253/31/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTRLadRxN/AFGMFirst Trust Germany AlphaDEX FundN/AFPAFirst Trust Asia Pacific ex-Japan AlphaDEX FundN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/AInsider OwnershipCompanyInsider OwnershipCYTRLadRxN/AFGMFirst Trust Germany AlphaDEX FundN/AFPAFirst Trust Asia Pacific ex-Japan AlphaDEX FundN/AFTXHFirst Trust Nasdaq Pharmaceuticals ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableFGMFirst Trust Germany AlphaDEX Fund147,000300,000N/ANot OptionableFPAFirst Trust Asia Pacific ex-Japan AlphaDEX Fund147,000500,002N/ANot OptionableFTXHFirst Trust Nasdaq Pharmaceuticals ETF147,000550,000N/AOptionableCYTR, FGM, FPA, and FTXH HeadlinesRecent News About These CompaniesA Look at Pharma ETFs After Strong Q1 EarningsMay 8, 2025 | zacks.comFirst Trust Nasdaq BuyWrite Income ETF declares $0.207 dividendJanuary 22, 2025 | msn.comPharma ETFs in Focus Post Solid Q2 EarningsAugust 14, 2024 | zacks.comA Look at Pharma ETFs Post Q1 EarningsMay 7, 2024 | zacks.comJNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in FocusApril 17, 2024 | zacks.com3 Health Care ETFs You'll Want to Own When the Market RecoversAugust 3, 2022 | stocknews.comSurprising Analyst 12-Month Target For FTXHMay 25, 2022 | nasdaq.comFirst Trust Nasdaq Pharmaceuticals ETF declares quarterly distribution of $0.0488March 25, 2022 | seekingalpha.comSolid Q4 Earnings Fail to Impress Pharma ETFsFebruary 22, 2022 | nasdaq.comWave of Solid Q3 Earnings Push Pharma ETFs HigherNovember 9, 2021 | nasdaq.com4 ETF Strategies to Follow Warren Buffett's VisionAugust 19, 2021 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTR, FGM, FPA, and FTXH Company DescriptionsLadRx NASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.First Trust Germany AlphaDEX Fund NASDAQ:FGM$53.61 -0.27 (-0.50%) As of 03:57 PM EasternThe First Trust Germany AlphaDEX Fund (FGM) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Germany index. The fund tracks a tiered equal-weighted index of 40 companies selected from the S&P Germany BMI based on the S&P's AlphaDex selection methodology. FGM was launched on Feb 14, 2012 and is managed by First Trust.First Trust Asia Pacific ex-Japan AlphaDEX Fund NASDAQ:FPA$32.17 +0.81 (+2.58%) As of 12:59 PM EasternThe First Trust Asia Pacific Ex-Japan AlphaDEX Fund (FPA) is an exchange-traded fund that mostly invests in total market equity. The fund selects and weights 100 stocks from the S&P Asia Pacific Ex-Japan BMI Index based on their growth and value factors. FPA was launched on Apr 18, 2011 and is managed by First Trust.First Trust Nasdaq Pharmaceuticals ETF NASDAQ:FTXH$25.15 +0.05 (+0.20%) Closing price 03:50 PM EasternExtended Trading$25.15 +0.00 (+0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
